Nichole Tucker

Results from MOMENTUM and other phase 3 studies will be reviewed by the FDA as the regulatory body considers approval of momelotinib for patients with myelofibrosis and anemia.

In an interview with Targeted Oncology, Cary Gross, MD, discussed retrospective research that revealed testing and treatment disparities among Medicaid beneficiaries with advanced non–small cell lung cancer, and the steps needed to improve outcomes for the patient population.

By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.

Findings from the phase 2 DESTINY-Breast02 show that trastuzumab deruxtecan improves both progression-free and overall survival in patients with HER2-positive unresectable and/or metastatic breast cancer.

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.

Accelerated approval has been granted to trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic non-small cell lung cancer based on positive results from DESTINY-Lung02.

An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.

Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review.

In an interview with Targeted Oncology, Jennifer Moss, MD, discussed health-related quality-of-life in older, rural vs urban patients with cancer and survivors. She also explained factors contributing to the disparity and how to improve outcomes for the population.

Interim findings from the phase 1 DELLphi-300 shows that tarlatamab may induce responses in heavily-pretreated patients with small cell lung cancer.

Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.

High-dose REGN5678 combined with cemiplimab shows preliminary response elicitation in patients with metastatic castration-resistant prostate cancer.

Frontline treatment with ibrutinib, bendamustine, and rituximab showed a prolongation in progression-free survival along with a good response rate in older patients with mantle cell lymphoma.

The phase 3 RESILIENT trial of irinotecan liposomal injection vs topotecan failed to meet its primary end point of overall survival in patients with previously treated small cell lung cancer.

In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.

The phase 3 INTERLINK-1 study of monalizumab and cetuximab as treatment of recurrent or metastatic squamous cell carcinoma of the head and neck has been discontinued. The study did not meet its efficacy goal.

In an interview with Targeted Oncology, Lori Wirth, MD, discussed the evolving treatment landscape for NTRK fusion-positive thyroid cancers.

In the phase 3 CheckMate-914 clinical trial, the combination of nivolumab and ipilimumab did not achieve its primary end point of improvement in disease-free survival compared with the placebo control.

: On the heels of positive findings from the phase 1/1b AURELIO-03, 1 patient with an advanced/refractory solid tumor has been dosed with SOT101 and pembrolizumab in the follow-up study, AURELIO-04.

Long-term follow-up in the COLUMBUS study shows continued survival improvement with encorafenib plus binimetinib and impressive disease control in patients with BRAF V600-mutant melanoma.

Treatment with ITI-3000 has begun in a first-in-human, phase 1 study of patients with Merkel cell carcinoma.

The developer of OP-1250 anticipates working closely with the FDA to expedite the development of the drug for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer.

The phase 2 LOTIS-9 study of loncastuximab tesirine-lpyl combined with rituximab has been initiated with the dosing of the first patient with previously untreated diffuse large B-cell lymphoma.

Following positive phase 1 study results for eltanexor monotherapy in patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndrome, the FDA has granted the drug fast track status.

The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.

Patients with unresected locally advanced head and neck squamous cell carcinoma did not show a significant improvement in event-free survival when treated with pembrolizumab and concurrent chemoradiation followed by pembrolizumab maintenance in the phase 3 KEYNOTE-412 study.

The addition of brentuximab vedotin to standard chemotherapy achieved a 41% reduction in the risk of death in patients with advanced-stage Hodgkin lymphoma in the ECHELON-1 study.

The phase 3 ZILO-301 study will evaluate the combination of zilovertamab and ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

In an interview with Targeted Oncology, Cristian Tomasetti, PhD, discussed the role of circulating tumor DNA in understanding the need for adjuvant chemotherapy in patients with stage II colon cancer. He explained how circulating tumor DNA can signal a patient’s risk of disease recurrence after surgery.